Group items tagged

This Funding Opportunity Announcement (FOA) invites applications to provide infrastructure support for advancing development of specific high-priority areas of behavioral and social research of relevance to aging. The infrastructure support will facilitate research networks through meetings, conferences, small-scale pilots, short-term educational opportunities (such as intensive workshops, summer institutes, or visiting scholar programs), and dissemination to encourage growth and development of specified priority areas and build resources for advancing aging-relevant research in the field at large. Network applications are limited to the following areas: (1) Midlife Reversibility of Biobehavioral Risk Associated with Early Life Adversity, (2) Stress Measurement, (3) Reproducibility in the Social and Behavioral Sciences, (4) Life Course Health Disparities at Older Ages, (5) Genomics of Behavioral and Social Science, (6) Integrating Animal Models to Inform Behavioral and Social Research on Aging, and (7) Rural Aging.    

This Funding Opportunity Announcement (FOA) invites applications proposing research on the specific role of aging biology in the development, etiology and treatment of Alzheimer's disease. Aging is by far the main risk factor for most chronic diseases, a fact recognized by the field of geroscience. Recent advances in the fields of basic aging biology and geroscience now allow researchers to address mechanistically the role of aging in Alzheimers disease. Applications that make use of geroscience principles and test the role of different hallmarks of aging biology are specifically appropriate, while those focused solely on aging biology, or solely on Alzheimers disease will be deemed unresponsive to the FOA.

This Funding Opportunity Announcement (FOA) invites applications proposing research on the specific role of aging biology in the development, etiology and treatment of Alzheimer's disease. Aging is by far the main risk factor for most chronic diseases, a fact recognized by the field of geroscience. Recent advances in the fields of basic aging biology and geroscience now allow researchers to address mechanistically the role of aging in Alzheimers disease. Applications that make use of geroscience principles and test the role of different hallmarks of aging biology are specifically appropriate, while those focused solely on aging biology, or solely on Alzheimers disease will be deemed unresponsive to the FOA.

The goal of the GEMSSTAR program is to provide support for early-career physician-scientists trained in medical or surgical specialties or early-career dentist-scientists to launch careers as future leaders in aging- or geriatric-focused research. To achieve this goal, the GEMSSTAR FOA provides small grants to conduct transdisciplinary aging research that will yield pilot data and experience for subsequent aging research projects. The GEMSSTAR program also encourages candidates to seek out a supportive research environment to achieve the program's goal of fostering the development of early-career physician- and dentist-scientists in aging- or geriatric-focused research, particularly as it applies to their clinical specialty/discipline. In selecting GEMSSTAR awardees, NIA will consider the extent to which a candidate's environment is supportive of aging- or geriatric-focused research.

The Aging Interventions Testing Program (ITP) tests, under standardized conditions, potential intervention strategies which may decelerate the rate of aging in mammals. The rate of aging is to be measured by lifespan extension and/or improvements in health at later ages due to the intervention. The ITP has used lifespan as its primary outcome for an intervention, with limited studies on end-of-life pathologies and selected tests of health across the lifespan (health span). This FOA calls for renewal of the ITP with the following goals: 1) Continue to test compounds for effects on lifespan; 2) Increase histology and pathophysiology analyses at time of death; 3) Increase focused studies of health span on selected compounds.

This Funding Opportunity Announcement (FOA) invites early-stage physician and other health professional investigators with a commitment to aging and/or aging-related diseases to apply for this award to advance their research and leadership skills in their specialty and in the broader field of aging and geriatrics research. The National Institute on Aging is pursuing this initiative to recruit new investigators who have begun to establish research programs and who, through this award, will be ready to assume leadership roles in their field of expertise and will be poised to change theory, practice and health outcomes related to the health of older individuals. Unlike other mentored K awards, candidates for this award must have received competitively awarded research support as a PD/PI at the faculty level or have otherwise leveraged faculty-level research support to develop an independent line of research. They must show evidence of leadership in the clinical or research domain. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (RFA-AG-19-018).

This FOA invites applications on novel studies of the molecular mechanisms underlying metformin's effects on aging and longevity. The goal of this FOA is to support applications that will lead to an in-depth understanding of the molecular mechanisms that determine the effects of metformin, either beneficial or detrimental, in relation to aging and longevity. Research supported by this FOA should lead to new insights on and better understanding of metformin's effects on aging and aging-related diseases.

The involvement of small businesses in translational aging research could substantially hasten the pace at which scientific advances are transformed into commercial products to improve or maintain the health and functional independence of older adults. Therefore, this funding opportunity announcement (FOA) is intended to encourage a greater involvement by small businesses through the SBIR mechanism in transforming scientific advances in aging research into novel devices, products, health care practices and programs that will benefit the lives of older adults. For the purposes of this FOA, T1 translational research on aging is defined as the application of basic and clinical biomedical or basic behavioral and social research findings towards the development of new strategies for prevention and treatment of age-related pathologies. T1 translational research approaches could include the development of new research tools or improving existing technologies to diagnose, prevent or treat age-related conditions, functional decline and disability.

This FOA seeks applications that propose innovative research strategies aimed at increasing the understanding of the changes in cellular architecture that occur during the aging process. Studies on cytoskeleton structure and function, the impact of the cytoskeleton on intracellular organelle interactions, and signaling or regulatory molecules controlling cellular architecture will be considered. There is interest in studying the role of the cytoskeleton in nuclear-cytoplasmic communications, and in spatio-temporal relationships during the aging process and in age-related diseases.

This FOA seeks applications that propose innovative research strategies aimed at increasing the understanding of the changes in cellular architecture that occur during the aging process. Studies on cytoskeleton structure and function, the impact of the cytoskeleton on intracellular organelle interactions, and signaling or regulatory molecules controlling cellular architecture will be considered. There is interest in studying the role of the cytoskeleton in nuclear-cytoplasmic communications, and in spatio-temporal relationships during the aging process and in age-related diseases. 

This Funding Opportunity Announcement (FOA) is issued as an initiative of the NIH Blueprint for Neuroscience Research.  The Neuroscience Blueprint is a collaborative framework through which 15 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.nih.gov/).  The Neuroscience Blueprint is supporting a Lifespan Human Connectome Project (L-HCP) to extend the Human Connectome Project (HCP) (http://www.neuroscienceblueprint.nih.gov/connectome) to map connectivity in the developing, adult, and aging human brain.  The goal of this FOA is to solicit grant applications that propose to extend the experimental protocols developed through the HCP to children in the 0-5 year old age range to investigate the structural and functional changes that occur in the brain during typical development.  Related FOAs solicit applications that apply the HCP protocols to the 5-21 year old age range and to middle age and elderly adults to explore changes that occur during normal aging.  

The goal of this FOA is to advance research on the underlying basis for the transfer (or transposition) of aging phenotypes observed between young and old rodents and discovered through heterochronic parabiosis. Examples of transposed phenotypes include reversal of cardiac hypertrophy, partial restoration of cognitive function, improved vascularization, and repair of skeletal muscle after cryo-injury (anti-geronic transposition), or as accelerated loss of cognitive function and neurogenesis (pro-geronic transposition). Other transposed phenotypes, as revealed solely through heterochronic parabiosis, may also be reported in the literature. There are also reports of candidate factors found in circulation that might be causally related to the transposition of these aging phenotypes; these are termed "circulating geronic factors" for purposes of this FOA. To date, these are proteins and peptides that pass between the young and old mice joined by parabiosis, due to anastomosis of their circulatory systems. Based on these novel findings and this novel experimental paradigm, the specific objective of this FOA is to test whether these candidate geronic factors are necessary for the transposition of aging phenotypes. The focus is on phenotypes transposed in heterochronic parabiosis and the candidate factors which are present and functional at physiological concentrations in circulation.

The goal of this FOA is to advance research on the underlying basis for the transfer (or transposition) of aging phenotypes observed between young and old rodents and discovered through heterochronic parabiosis. Examples of transposed phenotypes include reversal of cardiac hypertrophy, partial restoration of cognitive function, improved vascularization, and repair of skeletal muscle after cryo-injury (anti-geronic transposition), or as accelerated loss of cognitive function and neurogenesis (pro-geronic transposition). Other transposed phenotypes, as revealed solely through heterochronic parabiosis, may also be reported in the literature. There are also reports of candidate factors found in circulation that might be causally related to the transposition of these aging phenotypes; these are termed "circulating geronic factors" for purposes of this FOA. To date, these are proteins and peptides that pass between the young and old mice joined by parabiosis, due to anastomosis of their circulatory systems. Based on these novel findings and this novel experimental paradigm, the specific objective of this FOA is to test whether these candidate geronic factors are necessary for the transposition of aging phenotypes. The focus is on phenotypes transposed in heterochronic parabiosis and the candidate factors which are present and functional at physiological concentrations in circulation.

The purpose of this FOA is to stimulate the development of innovative research strategies aimed at increasing the understanding of the molecular and cellular changes in the cytoskeleton that occur during the aging process.  Applications considering the effect of age on factors such as cytoskeleton structure and function, the impact of the cytoskeleton on intracellular organelle interactions, and signaling or regulatory molecules controlling cellular architecture are encouraged.  There is also interest in studying the role of the cytoskeleton in nuclear-cytoplasmic communications, and in spatio-temporal relationships during the aging process and in age-related diseases.

This Funding Opportunity Announcement (FOA) is issued as an initiative of the NIH Blueprint for Neuroscience Research.  The Neuroscience Blueprint is a collaborative framework through which 15 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.nih.gov/).  The Neuroscience Blueprint is supporting a Lifespan Human Connectome Project (L-HCP) to extend the Human Connectome Project (HCP) (http://www.neuroscienceblueprint.nih.gov/connectome) to map connectivity in the developing, adult, and aging human brain.  The goal of this FOA is solicit grant applications that propose to extend the experimental protocols developed through the HCP to middle-age and elderly adults to investigate the structural and functional changes that occur in the brain during typical aging.  A companion FOA is soliciting applications that apply the HCP protocols to children and adolescents to explore changes that occur during typical development. 

This FOA invites applications for a Demography and Economics of Aging and AD/ADRD Coordinating Center (CC) whose purpose is to act as a hub, serving the needs of both traditional Centers on the Demography and Economics of Aging (D&E Centers) and Centers on the Demography and Economics of Alzheimer's Disease and Alzheimer's Related Dementias (D&E Centers on AD/ADRD), as well as the needs of NIA program staff. The goals of the overall D&E Center program are to seed new lines of research in a) the demography and economics of aging and b) demography, economics and health services research relevant to AD/ADRD, and to grow the number of researchers engaged in these fields through a variety of research and infrastructure activities that are built around specific research themes. The purpose of the CC is to work collaboratively with all participating Center sites to: maintain an active multi-center website; disseminate Center research advances, activities and resources to the research community, policymakers and other relevant stakeholders; maintain a centralized database to track and synthesize progress and outcomes of Center and CC activities for the purpose of annual reporting to individual Centers and to NIA Program Staff, and for future program evaluation by NIA; arrange an annual in-person meeting; foster communication and collaborative activities within and across both D&E Center programs and with other NIA research Centers; serve as the point-of-contact for the overall D&E Centers program by NIA staff, other NIA Centers and the broader scientific community.      

The overall goal of this funding announcement is to solicit applications to investigate the central neural control of mobility in older adults without overt neurological diseases using innovative and cutting-edge methods that are emerging in neuroscience, geriatrics and mobility-related fields in aging research communities. This announcement also seeks information on the degree of plasticity in the aging brain and how this may be harnessed to maintain or improve mobility. Applicants are highly encouraged to adapt a multidisciplinary and collaborative approach that includes basic, clinical, and translational scientists. Mobility impairments are common in aging and are associated with a host of adverse events including disability and mortality. Identifying novel modifiable predictors of mobility decline will lead to mechanistic insights and the development of novel therapeutic interventions to enhance mobility as a person ages.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage basic or clinical research applications that investigate central neural mechanisms of age-related hearing loss in older adults and/or in relevant animal models. This FOA is driven by the need to address a major gap in our understanding of the central pathways and neural networks that are involved in hearing loss, and how these may be altered in the context of the aging brain, as well as how natural aging influences central auditory plasticity.

Older adults overwhelmingly prefer to stay in their homes and communities as they age. But millions of older individuals live in homes that lack accessibility features that support the ability to live safely and independently. In fact, the Census Bureau reveals that 1 in 3 older adult has trouble using some feature of their home. Another major concern in the risk of falling among older adults. Most serious falls occur in and around the home, and can be life-changing. Home modifications and repairs can help older adults age in place and maintain their independence. In many cases home modifications can also help prevent falls and other accidents in the home. The Administration on Aging, an agency within the Administration for Community Living, intends to award one cooperative agreement designed to address barriers to optimal access to and use of home modifications that support aging in place. The project will be expected to provide technical assistance and serve as a repository for home modification best practices and innovations that can be replicated at the local level.

This FOA invites applications on novel studies of the molecular mechanisms underlying metformins effects on aging and longevity. The goal of this FOA is to support applications that will lead to an in-depth understanding of the molecular mechanisms that determine the effects of metformin, either beneficial or detrimental, in relation to aging and longevity. Research supported by this FOA should lead to new insights and better understanding of metformins effects on aging and aging-related diseases.

Recent reports highlight the enormous spatial and temporal diversity of glia, even within the same glial cell type. This within-glial-cell-type heterogeneity evolves during aging, suggesting that subtypes of glia with distinct physiological roles could emerge to influence brain aging processes. The goal of this Funding Opportunity Announcement is to support research addressing critical knowledge gaps in our understanding of how these glial subpopulations could contribute to vulnerability and resilience to brain aging.

The Administration for Community Living (ACL)/U.S. Administration on Aging (AoA) is providing this competitive grant opportunity to eligible entities for the purpose of establishing and providing ongoing technical assistance and support and build upon past advancements and innovations in serving this older LGBT individuals through new, efficient and sustainable approaches for ensuring high quality and culturally competent service delivery. Under this Funding Opportunity Announcement (FOA), ACL/AoA plans to fund one (1) cooperative agreement at a federal funding level of up to $295,540 per year for two (2) years, pending the availability of Federal funds. Applicants to this FOA must demonstrate the capacity to work at the national level to provide training, technical assistance and support to aging network entities (State Units on Aging, Area Agencies on Aging, service providers), LGBT organizations, and older LGBT consumers. Further, applicants must demonstrate the support and active involvement of a range of stakeholders sufficiently broad so as to ensure that all requirements outlined in this FOA are addressed.